98%
921
2 minutes
20
Introduction: Only a small number of risk factors for pancreatic ductal adenocarcinoma (PDAC) has been established. Several studies identified a role of epigenetics and of deregulation of DNA methylation. DNA methylation is variable across a lifetime and in different tissues; nevertheless, its levels can be regulated by genetic variants like methylation quantitative trait loci (mQTLs), which can be used as a surrogate.
Materials And Methods: We scanned the whole genome for mQTLs and performed an association study in 14 705 PDAC cases and 246 921 controls. The methylation data were obtained from whole blood and pancreatic cancer tissue through online databases. We used the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case-Control Consortium genome-wide association study (GWAS) data as discovery phase and the Pancreatic Disease Research consortium, the FinnGen project and the Japan Pancreatic Cancer Research consortium GWAS as replication phase.
Results: The C allele of 15q26.1-rs12905855 showed an association with a decreased risk of PDAC (OR=0.90, 95% CI 0.87 to 0.94, p=4.93×10 in the overall meta-analysis), reaching genome-level statistical significance. 15q26.1-rs12905855 decreases the methylation of a 'C-phosphate-G' (CpG) site located in the promoter region of the antisense () gene which, when expressed, decreases the expression of the RCC1 domain-containing () gene (part of a histone demethylase complex). Thus, it is possible that the rs12905855 C-allele has a protective role in PDAC development through an increase of gene expression, made possible by the inactivity of .
Conclusion: We identified a novel PDAC risk locus which modulates cancer risk by controlling gene expression through DNA methylation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/jmg-2022-108910 | DOI Listing |
Comput Assist Surg (Abingdon)
December 2025
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
To develop a DeepSurv model for predicting survival in pancreatic adenocarcinoma patients, evaluating the benefit of surgical versus non-surgical treatment across different stages, including stage IV subcategories. Clinical data were extracted from the SEER database (2000-2020). Patients were randomly divided into a model-building group and an experimental group.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
University of Pennsylvania, Philadelphia, PA, United States.
Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).
View Article and Find Full Text PDFEndocr Relat Cancer
September 2025
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
Bone metastases (BMs) are rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and S.
View Article and Find Full Text PDFJ Biomed Opt
December 2025
University of Toronto, Department of Medical Biophysics, Temerty Faculty of Medicine, Toronto, Ontario, Canada.
Significance: Tumor tissues exhibit contrast with healthy tissue in circular degree of polarization (DOP) images via higher magnitude circular DOP values and increased helicity-flipping. This phenomenon may enable polarimetric tumor detection and surgical/procedural guidance applications.
Aim: Depolarization metrics have been shown to exhibit differential responses to healthy and cancer tissue, whereby tumor tissues tend to induce less depolarization; however, the understanding of this depolarization-based contrast remains limited.
Front Oncol
August 2025
Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Introduction: Pancreatic adenocarcinoma (PAAD) is a highly aggressive malignancy characterized by a profoundly hypoxic tumor microenvironment, which fosters tumor progression and confers resistance to therapy The oncogenic regulator ID1has been implicated in PAAD malignancy, however, the mechanisms underlying hypoxia-induced stabilization of ID1 and the role of ubiquitin-mediated degradation remain poorly understood. Elucidating these pathways is essential for identifying novel therapeutic targets for PAAD.
Methods: In this study, we examined ID1 expression in PAAD tissues and cell lines using publicly available databases and in vitro models.